J
Jeffrey L. Lennox
Researcher at Emory University
Publications - 95
Citations - 7717
Jeffrey L. Lennox is an academic researcher from Emory University. The author has contributed to research in topics: Viral load & Raltegravir. The author has an hindex of 42, co-authored 94 publications receiving 7236 citations. Previous affiliations of Jeffrey L. Lennox include Grady Memorial Hospital.
Papers
More filters
Journal ArticleDOI
Developing Treatment Guidelines During a Pandemic Health Crisis: Lessons Learned From COVID-19.
Safia S Kuriakose,Kanal Singh,Alice K. Pau,Eric S. Daar,Rajesh T. Gandhi,Pablo Tebas,Laura Evans,Roy M. Gulick,H. Clifford Lane,Henry Masur,Judith A. Aberg,Adaora A. Adimora,Jason V. Baker,Lisa Baumann Kreuziger,Roger Bedimo,Pamela S. Belperio,Stephen V. Cantrill,Craig M. Coopersmith,Susan L Davis,Amy L. Dzierba,John J. Gallagher,David V. Glidden,Birgit Grund,Erica J. Hardy,Carl Hinkson,Brenna L. Hughes,Steven T. Johnson,Marla J. Keller,Arthur Y. Kim,Jeffrey L. Lennox,Mitchell M. Levy,Jonathan Z. Li,Greg S. Martin,Susanna Naggie,Andrew T. Pavia,Nitin Seam,Steven Q. Simpson,Susan Swindells,Phyllis C. Tien,Alpana Waghmare,Kevin C. Wilson,Jinoos Yazdany,Philip Zachariah,Danielle Campbell,Carly Harrison,Timothy Burgess,Joseph Francis,Virginia Sheikh,Timothy M. Uyeki,Robert L. Walker +49 more
TL;DR: The development of the National Institutes of Health (NIH) COVID-19 Treatment Guidelines began in March 2020 in response to a request from the White House Coronavirus Task Force as discussed by the authors.
Journal ArticleDOI
Outcomes for Critically Ill Patients With HIV and Severe Sepsis in the Era of Highly Active Antiretroviral Therapy
TL;DR: In this paper, the etiology of acute infections in critically ill patients with HIV and the factors that affect in-hospital mortality were investigated, showing that acute infections were associated with acute illness severity, but not clearly associated with variables related to HIV infection.
Journal ArticleDOI
Antiretroviral Therapy-Induced Bone Loss Is Durably Suppressed by a Single Dose of Zoledronic Acid in Treatment-Naive Persons with Human Immunodeficiency Virus Infection: A Phase IIB Trial.
Ighovwerha Ofotokun,Ighovwerha Ofotokun,Lauren F Collins,Lauren F Collins,Kehmia Titanji,Antonina Foster,Caitlin A. Moran,Caitlin A. Moran,Anandi N. Sheth,Anandi N. Sheth,Cecile D. Lahiri,Cecile D. Lahiri,Jeffrey L. Lennox,Jeffrey L. Lennox,Laura Ward,Kirk A. Easley,M. Neale Weitzmann,M. Neale Weitzmann +17 more
TL;DR: A single dose of ZOL administered at ART initiation blunts bone resorption and BMD loss at key fracture-prone anatomical sites in treatment-naïve PWH for 3 years following ART initiation.
Journal Article
Efficacy and Tolerability of 3 Nonnucleoside Reverse Transcriptase Inhibitor-Sparing Antiretroviral Regimens for Treatment-Naive Volunteers Infected With HIV-1 (vol 161, pg 461, 2014)
Jeffrey L. Lennox,Raphael J. Landovitz,Heather J. Ribaudo,Ighovwerha Ofotokun,Lumine H. Na,Catherine Godfrey +5 more
Posted ContentDOI
Tissue specificity-aware TWAS (TSA-TWAS) framework identifies novel associations with metabolic, immunologic, and virologic traits in HIV-positive adults
Binglan Li,Yogasudha Veturi,Anurag Verma,Yuki Bradford,Eric S. Daar,Roy M. Gulick,Sharon A. Riddler,Gregory K. Robbins,Jeffrey L. Lennox,David W. Haas,David W. Haas,Marylyn D. Ritchie +11 more
TL;DR: A tissue specificity-aware TWAS (TSA-TWAS) analytic framework was applied to look for gene-based associations with pre-treatment laboratory values from AIDS Clinical Trial Group (ACTG) studies and found that cross-tissue identification of expression quantitative trait loci (eQTLs) improved TWAS power.